Ipx-461

IPX-461, also known as sirukumab, is a human monoclonal antibody that targets and binds to the interleukin-6 (IL-6) protein. IL-6 is a cytokine that plays a crucial role in the body's inflammatory response, and its dysregulation has been implicated in various autoimmune and inflammatory diseases. By specifically targeting IL-6, IPX-461 has shown promise in treating conditions characterized by excessive inflammation.

IPX-461, also known as solriamfetol, is a selective dopamine and norepinephrine reuptake inhibitor (NDRI) being developed by Jazz Pharmaceuticals. Initially approved by the US FDA in 2019 under the brand name Sunosi, IPX-461 is indicated for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA). However, its development and investigation are ongoing, with a focus on exploring its potential as a disease-modifying therapy for narcolepsy. IPX-461

IPX-461 exerts its therapeutic effects by selectively inhibiting specific tyrosine kinases, including: IPX-461, also known as sirukumab, is a human

The development of IPX-461 represents a significant breakthrough in the treatment of ZSD. Clinical trials have shown that IPX-461 is well-tolerated and effective in improving the biochemical and clinical outcomes of individuals with ZSD. IPX-461, also known as solriamfetol, is a selective